Moreover, BETd-260 treatment augmented the expression of two typical apoptosis biomarkers, cleaved form of PARP, activated form of caspase-3 in HCC tumor tissue, suggesting that BET-PROTAC BETd-260 reciprocally modulates Mcl-1 and Bad, triggers apoptosis in HCC xenograft tumor tissues. This evidence concerns the gene BAD and hepatocellular carcinoma.